HILPDA promotes NASH-driven HCC development by restraining intracellular fatty acid flux in hypoxia
Davide Povero,Yongbin Chen,Meixia Pan,Hanmei Bao,Emily Blake,Yue Yu,Timucin Taner,Xianlin Han,Jun Liu,Scott M. Johnson,Cailin E. McMahon,Xuan-Mai T. Petterson,Kimberly P. Lauer,Daniel R. O’Brien,Rondell P. Graham,Gina L. Razidlo
DOI: https://doi.org/10.1016/j.jhep.2023.03.041
IF: 25.7
2023-04-15
Journal of Hepatology
Abstract:Background & Aims Nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) is rapidly rising and lacks effective therapies, yet the underlying mechanisms remain unclear. This study aims to determine the role of hypoxia-inducible lipid droplet associated protein (HILPDA), a selective inhibitor of intracellular lipolysis, in NASH-HCC. Methods Clinical significance of HILPDA was assessed in human NASH-HCC specimens by immunohistochemistry and transcriptomics analyses. The oncogenic effect of HILPDA was assessed in human HCC cells and in 3D epithelial spheroids upon exposure to free fatty acids and either normoxia or hypoxia. Lipidomics profiling of WT and HILPDA knockout HCC cells was assessed via shotgun and targeted approaches. WT (HILPDA fl/fl ) and HILPDA hepatocyte-specific knockout (HILPDA ΔHep ) mice were fed a western diet and high sugar in drinking water while receiving carbon tetrachloride to induce NASH-driven HCC. Results In patients with NASH-driven HCC, upregulated HILPDA expression is strongly associated with poor survival. In oxygen-deprived and lipid-loaded culture conditions, HILPDA promotes viability of human hepatoma cells and growth of 3D epithelial spheroids. Lack of HILPDA triggered flux of polyunsaturated fatty acids to membrane phospholipids and of saturated fatty acids to ceramide synthesis, exacerbating lipid peroxidation and apoptosis in hypoxia. The apoptosis induced by HILPDA deficiency was reversed by pharmacological inhibition of ceramide synthesis. In our experimental mouse model of NASH-driven HCC, HILPDA ΔHep reduced hepatic steatosis and tumorigenesis while increasing oxidative stress in the liver. Single cell analysis supports a dual role of hepatic HILPDA in protecting HCC cells and facilitating the establishment of a pro-tumorigenic immune microenvironment in NASH. Conclusions Hepatic HILPDA is a pivotal oncometabolic factor in the NASH liver microenvironment and represents a novel potential therapeutic target. Impact And Implications Nonalcoholic steatohepatitis (NASH, chronic metabolic liver disease caused by buildup of fat, inflammation and damage in the liver) is emerging as the leading risk factor and the fastest growing cause of hepatocellular carcinoma (HCC), the most common form of liver cancer. While curative therapeutic options exist for HCC, it frequently presents at a late stage when such options are no longer effective and only systemic therapies are available. However, systemic therapies are still associated with poor efficacy and some side effects. In addition, no approved drugs are available for NASH. Therefore, understaing the underlying metabolic alterations occurring during NASH-HCC is key to identify new cancer treatments that target the unique metabolic needs of cancer cells.
gastroenterology & hepatology